Search

Displaying results 131 - 140 of 4018 in total
  1. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … [L41469] On December 17, 2025, the U.S.

  2. Target

    Disulfide bond formation protein B

    go.drugbank.com/bio_entities/BE0004378
    TargetEscherichia coli (strain K12)

    Required for disulfide bond formation in some periplasmic proteins such as PhoA or OmpA. Acts by oxidizing the DsbA protein.

    Polypeptides: Disulfide bond formation protein B
  3. Drug

    Calcium

    go.drugbank.com/drugs/DB01373
    ApprovedInvestigationalNutraceutical

    Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium.

    Mixtures: BION 3 FILM COATED TABLETCategories: Drugs for Treatment of Bone Diseases, Drugs Affecting Bone Structure and Mineralization
  4. Indication

    High risk, refractory Neuroblastomas of the bone or bone marrow

    go.drugbank.com/conditions/DBCOND0134732
    Drugs: Naxitamab
    Synonyms: High risk, refractory Neuroblastomas of the bone or bone marrow
  5. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    ApprovedInvestigational

    Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation. … [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

  6. Drug

    Alendronic acid

    go.drugbank.com/drugs/DB00630
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  7. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.

  8. Drug

    Choline C-11

    go.drugbank.com/drugs/DB09563
    Approved

    Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized

  9. Drug

    Etidronic acid

    go.drugbank.com/drugs/DB01077
    ApprovedInvestigational

    [A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901]

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  10. Target

    F-box only protein 41

    go.drugbank.com/bio_entities/BE0009024
    TargetHumans

    Substrate-recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex. Required in the developing brain for neuronal migration and long-term cerebellar integrity.

    Polypeptides: F-box only protein 41